Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
ARA-290 binds the innate-repair (a heterodimer of EPO-R and the β common receptor) found on inflammatory and injured tissue. This selective targeting is associated with tissue-protective and anti-inflammatory effects without stimulating red-blood-cell production.
02
Research applications
- Small-fibre neuropathy clinical research (sarcoidosis, diabetes)
- Inflammation and tissue-protection research
- Innate-repair pharmacology
- Transplantation and islet-protection research
Evidence at a glance
What's behind this profile
3 citations · 2013–2016
- Animal
- 1
- Review
- 1
- Other
- 1
Studies in rodents or other animal models.
Narrative or systematic reviews; no primary data.
Studies that did not match the categories above.
Publication years
- 13
- 14
- 15
- 16
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 1 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
ARA 290 for treatment of small fiber neuropathy in sarcoidosis
2014
van Velzen M et al. · Expert Opinion on Investigational Drugs
- Model
- Review of Phase II clinical trials in sarcoidosis small-fibre neuropathy
- Sample
- N/A (clinical-trial review)
Reviewed Phase II data in which ARA-290 was associated with improvements in neuropathic pain, corneal nerve fibre density, and quality of life in sarcoidosis-related small-fibre neuropathy.
A Nonhematopoietic Erythropoietin Analogue, ARA 290, Inhibits Macrophage Activation and Prevents Damage to Transplanted Islets
2016
Watanabe M et al. · Transplantation
- Model
- In vitro macrophage assays + in vivo marginal pancreatic islet transplantation in diabetic mice
- Sample
- Diabetic mice receiving 185 islets each
ARA 290 was associated with suppressed inflammatory responses and reduced islet damage in the transplantation model used.
ARA 290 (cibinetide) editorial commentary
2013
Tracey KJ et al. · Molecular Medicine
- Model
- Editorial framing of ARA-290 development
- Sample
- N/A (editorial)
Editorial commentary positioning ARA-290 within the broader context of non-hematopoietic erythropoietin- research.
Evidence caveats
- ARA-290 is investigational. Primary published evidence is from small Phase II trials and preclinical models.
- Subsequent late-phase clinical development has been limited; long-term safety and efficacy in humans have not been established in broad peer-reviewed databases.
04
Storage and handling
Trial material follows the clinical trial protocol cold-chain. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Trial material follows the clinical trial protocol cold-chain.
- Research-grade material requires controlled laboratory storage and batch traceability.
- Investigational — not for unsupervised use.